New research sheds more light on secondary tumours with Roche/Plexxikon's Zelboraf
This article was originally published in Scrip
Executive Summary
Researchers have proposed a mechanism for the accelerated secondary tumour development seen in some melanoma patients receiving BRAF inhibitors such as Roche/Plexxikon's (Daiichi Sankyo) Zelboraf (vemurafenib) and suggested the possible use of alternative or complementary therapies as a preventative measure.